Walleye Capital’s ZyVersa Therapeutics ZVSA Stock Holding History

Walleye Capital’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,802	Closed	-$128K	–	5617
2023 Q3	$128K	Buy	+2,802	New	+$167K	﹤0.01%	3814

Other funds holding ZVSA

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Walleye Capital's ZVSA Position: Q4 2023 in Review

Walleye Capital sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 2,802 shares — an estimated $128K sold.

Walleye Capital first reported a position in ZVSA in Q3 2023 and held it in 1 quarter. The position peaked at $128K in Q3 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

Walleye Capital reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 2,802 ZyVersa Therapeutics shares in Q4 2023, an estimated $128K.
Walleye Capital first reported a position in ZyVersa Therapeutics in Q3 2023 and held it in 1 quarter.
Walleye Capital's ZyVersa Therapeutics position peaked at $128K in Q3 2023.
6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.